{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T20:26:39Z","timestamp":1787257599060,"version":"build-2736575974"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T00:00:00Z","timestamp":1658188800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Skin and soft tissue infections (SSTIs) are among the most common infections worldwide. They manifest in a variety of forms, such as erysipelas, cellulitis, and necrotizing fasciitis. Antibiotics are the significant method for clinical treatment of SSTIs. This study reported a methodology framework to determine the efficacy and safety of iclaprim in treatment of SSTIs.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> We will search the PubMed, EMbase, CNKI, WanFang Data, VIP, and <jats:ext-link>ClinicalTrials.gov<\/jats:ext-link> from their inception to June 2022 for randomized controlled trials and cohort studies on iclaprim with SSTIs. Two authors will independently screen the eligible studies, assess the quality of the included papers, and extract the required information. Randomized controlled trials will be assessed using the Cochrane risk-of-bias tool. The Newcastle\u2013Ottawa Scale will be used to evaluate observational studies. The quality of the evidence will be evaluated using the Grading of Recommendations Assessment Development and Evaluation system. RevMan 5.3 will be used for the data synthesis and quantitative analysis.<\/jats:p><jats:p><jats:bold>Results and Discussions:<\/jats:bold> This study will provide the clinicians with more high-quality evidence to choose iclaprim for patients with SSTIs.<\/jats:p><jats:p><jats:bold>Ethics and Dissemination:<\/jats:bold> This systematic review and meta-analysis will be based on published data, so ethical approval is not necessary. The results of this meta-analysis will be published in a peer-reviewed journal.<\/jats:p>","DOI":"10.3389\/fphar.2022.932688","type":"journal-article","created":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T08:17:53Z","timestamp":1658218673000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and Safety of Iclaprim for the Treatment of Skin Structures and Soft Tissue Infections: A Methodological Framework"],"prefix":"10.3389","volume":"13","author":[{"given":"Lian","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linli","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingmin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.mib.2005.07.001","article-title":"Recently Approved and Investigational Antibiotics for Treatment of Severe Infections Caused by Gram-Positive Bacteria","volume":"8","author":"Appelbaum","year":"2005","journal-title":"Curr. Opin. Microbiol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ijid.2017.05.002","article-title":"Staphylococcus aureus Soft Tissue Infection May Increase the Risk of Subsequent Staphylococcal Soft Tissue Infections","volume":"60","author":"Bouvet","year":"2017","journal-title":"Int. J. Infect. Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"178","DOI":"10.3201\/eid0702.010204","article-title":"The Changing Epidemiology of Staphylococcus aureus?","volume":"7","author":"Chambers","year":"2001","journal-title":"Emerg. Infect. Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1086\/422458","article-title":"Staphylococcus aureus with Reduced Susceptibility to Vancomycin","volume":"39","author":"Cosgrove","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"B5","article-title":"Clinical Efficacy of Iclaprim in Complicated Skin and Skin Structure Infection (cSSSI): Preliminary Results from the ASSIST-2 Clinical Trial","author":"Dryden","year":"2008"},{"key":"B6","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE Guidelines: 1. Introduction-GRADE Evidence Profiles and Summary of Findings Tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J. Clin. Epidemiol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1001\/archinte.168.14.1585","article-title":"National Trends in Ambulatory Visits and Antibiotic Prescribing for Skin and Soft-Tissue Infections","volume":"168","author":"Hersh","year":"2008","journal-title":"Arch. Intern Med."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02580-17","article-title":"A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim versus Vancomycin for Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed to Be Due to Gram-Positive Pathogens (REVIVE-2 Study)","volume":"62","author":"Holland","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"B9","doi-asserted-by":"publisher","first-page":"115013","DOI":"10.1016\/j.diagmicrobio.2020.115013","article-title":"Worldwide Surveillance of Iclaprim Activity: In Vitro Susceptibility of Gram-Positive Pathogens Collected from Patients with Skin and Skin Structure Infections from 2013 to 2017","volume":"97","author":"Huang","year":"2020","journal-title":"Diagn Microbiol. Infect. Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.ijantimicag.2018.05.012","article-title":"Pooled Analysis of the Phase 3 REVIVE Trials: Randomised, Double-Blind Studies to Evaluate the Safety and Efficacy of Iclaprim versus Vancomycin for Treatment of Acute Bacterial Skin and Skin-Structure Infections","volume":"52","author":"Huang","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B11","doi-asserted-by":"publisher","first-page":"957","DOI":"10.2217\/fmb-2018-0061","article-title":"Iclaprim, a Dihydrofolate Reductase Inhibitor Antibiotic in Phase III of Clinical Development: a Review of its Pharmacology, Microbiology and Clinical Efficacy and Safety","volume":"13","author":"Huang","year":"2018","journal-title":"Future Microbiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.diagmicrobio.2018.09.002","article-title":"Surveillance of Iclaprim Activity: In Vitro Susceptibility of Gram-Positive Skin Infection Pathogens Collected from 2015 to 2016 from North America and Europe","volume":"93","author":"Huang","year":"2019","journal-title":"Diagn Microbiol. Infect. Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1093\/cid\/cix987","article-title":"A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim vs Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed to Be Due to Gram-Positive Pathogens: REVIVE-1","volume":"66","author":"Huang","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens10020158","article-title":"Bacteria and Host Interplay in Staphylococcus aureus Septic Arthritis and Sepsis","volume":"10","author":"Jin","year":"2021","journal-title":"Pathog. (Basel, Switz."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.3201\/eid1308.061575","article-title":"Skin and Soft Tissue Infections Caused by Methicillin-Resistant Staphylococcus aureus USA300 Clone","volume":"13","author":"Johnson","year":"2007","journal-title":"Emerg. Infect. Dis."},{"key":"B35","doi-asserted-by":"crossref","first-page":"e29035","DOI":"10.1097\/MD.0000000000029035","article-title":"External Treatment of Herbal Medicine with Tuina in Congenital Muscular Torticollis: A Protocol for Systematic Review and Meta-Analysis","volume":"101","author":"Kim","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2834","DOI":"10.1128\/AAC.01383-08","article-title":"Multicenter, Randomized Study of the Efficacy and Safety of Intravenous Iclaprim in Complicated Skin and Skin Structure Infections","volume":"53","author":"Krievins","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"B17","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1007\/s00284-014-0770-x","article-title":"Biofilm Formation by Staphylococcus aureus Isolates from Skin and Soft Tissue Infections","volume":"70","author":"Kwiecinski","year":"2015","journal-title":"Curr. Microbiol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"A245","DOI":"10.1016\/j.jval.2015.03.1424","article-title":"Incidence and Cost of Skin and Soft Tissue Infections in the united States","volume":"18","author":"Lee","year":"2015","journal-title":"Value Health"},{"key":"B36","doi-asserted-by":"crossref","first-page":"859469","DOI":"10.3389\/fpubh.2022.859469","article-title":"HIV Serostatus Disclosure and Its Predictors Among Children Living With HIV in Ethiopia: A Systematic Review and Meta-Analysis","volume":"10","author":"Lemma","year":"2022","journal-title":"Front Public Health"},{"key":"B37","doi-asserted-by":"crossref","first-page":"e057671","DOI":"10.1136\/bmjopen-2021-057671","article-title":"Efficacy and Safety of Whole-Lung Lavage for Pulmonary Alveolar Proteinosis: a Protocol for a Systematic Review and Meta-Analysis","volume":"12","author":"Liu","year":"2022","journal-title":"BMJ Open"},{"key":"B19","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1186\/s12879-015-1071-0","article-title":"Incidence of Skin and Soft Tissue Infections in Ambulatory and Inpatient Settings, 2005-2010","volume":"15","author":"Miller","year":"2015","journal-title":"BMC Infect. Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1099\/jmm.0.001177","article-title":"A Pooled Analysis of Patients with Wound Infections in the Phase 3 REVIVE Trials: Randomized, Double-Blind Studies to Evaluate the Safety and Efficacy of Iclaprim versus Vancomycin for Treatment of Acute Bacterial Skin and Skin Structure Infections","volume":"69","author":"Noviello","year":"2020","journal-title":"J. Med. Microbiol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1080\/14787210.2018.1536545","article-title":"Iclaprim: a Differentiated Option for the Treatment of Skin and Skin Structure Infections","volume":"16","author":"Noviello","year":"2018","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1093\/jac\/dkp024","article-title":"Increased Hydrophobic Interactions of Iclaprim with Staphylococcus aureus Dihydrofolate Reductase Are Responsible for the Increase in Affinity and Antibacterial Activity","volume":"63","author":"Oefner","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"key":"B23","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/82_2016_32","article-title":"Staphylococcus Aureus-Associated Skin and Soft Tissue Infections: Anatomical Localization, Epidemiology, Therapy and Potential Prophylaxis","volume":"409","author":"Olaniyi","year":"2017","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 Statement: an Updated Guideline for Reporting Systematic Reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"key":"B25","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1016\/S1198-743X(16)30095-7","article-title":"Current and Future Trends in Antibiotic Therapy of Acute Bacterial Skin and Skin-Structure Infections","volume":"22","author":"Russo","year":"2016","journal-title":"Clin. Microbiol. Infect."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1128\/AAC.00129-09","article-title":"Potency and Bactericidal Activity of Iclaprim against Recent Clinical Gram-Positive Isolates","volume":"53","author":"Sader","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"B27","doi-asserted-by":"publisher","first-page":"4217","DOI":"10.1016\/j.bmcl.2003.07.023","article-title":"Iclaprim, a Novel Diaminopyrimidine with Potent Activity on Trimethoprim Sensitive and Resistant Bacteria","volume":"13","author":"Schneider","year":"2003","journal-title":"Bioorg Med. Chem. Lett."},{"key":"B28","doi-asserted-by":"publisher","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015: Elaboration and Explanation","volume":"350","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1345\/aph.1L167","article-title":"Iclaprim, a Novel Diaminopyrimidine for the Treatment of Resistant Gram-Positive Infections","volume":"43","author":"Sincak","year":"2009","journal-title":"Ann. Pharmacother."},{"key":"B30","article-title":"Efficacy of Iclaprim in Complicated Skin and Skin Structure Infections: Preliminary Results of ASSIST-1","author":"Stevens","year":"2007"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.1093\/cid\/ciu444","article-title":"Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America","volume":"59","author":"Stevens","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1128\/aac.48.1.275-280.2004","article-title":"Vancomycin-resistant Staphylococcus aureus Isolate from a Patient in Pennsylvania","volume":"48","author":"Tenover","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"B33","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1111\/j.1468-3083.2011.04416.x","article-title":"Bacterial Skin and Soft Tissue Infections: Review of the Epidemiology, Microbiology, Aetiopathogenesis and Treatment: a Collaboration between Dermatologists and Infectivologists","volume":"26","author":"Tognetti","year":"2012","journal-title":"J. Eur. Acad. Dermatol Venereol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1128\/AAC.01568-12","article-title":"Systematic Review and Meta-Analysis of Vancomycin-Induced Nephrotoxicity Associated with Dosing Schedules that Maintain Troughs between 15 and 20 Milligrams Per Liter","volume":"57","author":"van Hal","year":"2013","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.932688\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T08:17:58Z","timestamp":1658218678000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.932688\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,19]]},"references-count":37,"alternative-id":["10.3389\/fphar.2022.932688"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.932688","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,19]]},"article-number":"932688"}}